Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP vs XT in Advanced Esophageal Squamous Cell Carcinoma
NCT00816634Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Oct 2008
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
capecitabinepaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT00816634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816634.